AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2025

Nov 14, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2025-11-12

Reporting Person: Scadden David (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-12	Common stock	M	200	$18.09	Acquired	17803	Direct
2025-11-12	Common stock	S	200	$43.84	Disposed	17603	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-12	Stock options (right to buy)	$18.09	M	200	Disposed	2032-06-21	Common stock (200)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date.